WO2023218430 - METHODS OF TREATING RETINAL DEGENERATIVE DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR MIR‑142 AND COMPOSITIONS THEREOF

National phase entry:
Publication Number WO/2023/218430
Publication Date 16.11.2023
International Application No. PCT/IB2023/054956
International Filing Date 13.05.2023
Title **
[English] METHODS OF TREATING RETINAL DEGENERATIVE DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR MIR‑142 AND COMPOSITIONS THEREOF
[French] MÉTHODES DE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES DE LA RÉTINE UTILISANT AIMP2-DX2 ET ÉVENTUELLEMENT UNE SÉQUENCE CIBLE POUR MIR142 ET COMPOSITIONS ASSOCIÉES
Applicants **
GENEROATH CO., LTD.
Inventors
CHOI, Jin Woo
BAEK, Kyunghwa
Priority Data
63/341,798   13.05.2022   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3020
EPO Filing, Examination, Granting19127
Japan Filing, Examination, Granting2591
South Korea Filing, Examination, Granting2215
USA Filing, Examination, Granting6390
MasterCard Visa
Total: 33,343

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Disclosed herein are methods of treating retinal degenerative diseases, comprising administering to a subject in need thereof a vector comprising AIMP2-DX2 and optionally a target sequence for miR-142.[French] Sont présentement divulguées des méthodes de traitement de maladies dégénératives de la rétine, comprenant l'administration à un sujet qui en a besoin d'un vecteur comprenant AIMP-DX2 et éventuellement une séquence cible pour miR-142.